Krystal Biotech, Inc. KRYS Accrued Liabilities & Other
Accrued Liabilities & Other at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s accrued liabilities & other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s accrued liabilities & other?
- Krystal Biotech, Inc. (KRYS) reported accrued liabilities & other of $31.2M in Q1 2026.
- How has Krystal Biotech, Inc.'s accrued liabilities & other changed year-over-year?
- Krystal Biotech, Inc.'s accrued liabilities & other increased by 11.2% year-over-year, from $28.05M to $31.2M.
- What is the long-term trend for Krystal Biotech, Inc.'s accrued liabilities & other?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s accrued liabilities & other has grown at a 128.5% compound annual growth rate (CAGR), from $638K to $39.75M.
- What does accrued liabilities & other mean?
- Miscellaneous short-term expenses that the company has incurred but not yet paid.
- How do you interpret accrued liabilities & other?
- Fluctuations often track with the company's operational scale and timing of periodic expenses like bonuses or annual service fees.
- How does accrued liabilities & other compare across companies?
- Standard across all industries; peers will have similar accruals based on their specific operational cost structures.